---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-007212"
form_type: "8-K"
ticker: "IRWD"
cik: "0001446847"
company_name: "IRONWOOD PHARMACEUTICALS INC"
filed_at: "2025-01-29T23:59:59+00:00"
generated_at: "2026-05-27T06:41:56.469518+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Ironwood cuts workforce ~50%, promotes Gregory Martini to CFO

## Summary
- Workforce reduction of ~50% approved Jan 17, targeting primarily field-based sales employees; affected employees notified Jan 29.
- Expects to incur $20M-$25M in charges, mostly severance and benefits, substantially in H1 2025; post-reduction headcount ~120.
- Gregory Martini promoted to SVP, CFO effective Jan 27; succeeds Thomas McCourt who remains CEO.
- Martini receives base salary $485k, bonus target 45%, and 111,111 RSUs vesting over 4 years.

## SEC filing metadata
- accession: 0001104659-25-007212
- form_type: 8-K
- ticker: IRWD
- cik: 0001446847
- company_name: IRONWOOD PHARMACEUTICALS INC
- filed_at: 2025-01-29T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.05, 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1446847/000110465925007212/0001104659-25-007212-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1446847/000110465925007212/tm254830d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-007212
- JSON: https://secwatch.observer/filing/0001104659-25-007212.json
- Plain text: https://secwatch.observer/filing/0001104659-25-007212.txt

## Key facts
- Executive change
  Gregory Martini was appointed as Senior Vice President, Chief Financial Officer at IRONWOOD PHARMACEUTICALS INC.
  - Action: promoted
  - Role: Senior Vice President, Chief Financial Officer
  source text: the Company announced the promotion of Gregory Martini, 36, to Senior Vice President, Chief Financial Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1446847/000110465925007212/0001104659-25-007212-index.htm
- Executive change
  Thomas McCourt changed role as principal executive officer at IRONWOOD PHARMACEUTICALS INC.
  - Action: relinquished principal financial officer role
  - Role: principal executive officer
  source text: Mr. Martini will assume the responsibilities of the Company’s principal financial officer from Thomas McCourt, who will remain the Company’s principal executive officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1446847/000110465925007212/0001104659-25-007212-index.htm
- Restructurings & Charges
  IRONWOOD PHARMACEUTICALS INC announced a restructuring with charges of approximately $20.0 million to approximately $25.0 million (approximately 50%).
  - Type: restructuring
  - Charge: approximately $20.0 million to approximately $25.0 million
  - Headcount: approximately 50%
  source text: to have approximately 120 full-time employees. The Company estimates that, in connection with this reduction in its workforce, it will incur aggregate charges of approximately $20.0 million to approximately $25.0 million, primarily comprised of one-time employee severance and benefit costs. The charges related to the reduction in workforce are expected to be
  evidence_url: https://www.sec.gov/Archives/edgar/data/1446847/000110465925007212/0001104659-25-007212-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.